Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Rome, Italy during the COVID-19 Outbreak.
Diagnostics (Basel)
; 11(7)2021 Jun 24.
Article
in English
| MEDLINE | ID: covidwho-1288826
ABSTRACT
BACKGROUND:
this study aimed to determine the proportion of people living with HIV (PLWH) with anti-SARS-CoV-2 IgG antibodies in a large sample from a single HIV referral center in Rome, Italy; the time-frame included both the first and the second wave of the Italian COVID-19 pandemic;Methods:
we conducted a cross-sectional study on stored cryopreserved samples from 1 March 2020 to 30 November 2020. Total antibodies against SARS-CoV-2 were preliminarily tested using a chemiluminescent immunoassay. Positive results were re-tested with an ELISA assay as an IgG confirmatory test;Results:
overall, 1389 samples were analyzed from 1106 PLWH 69% males, median age 53 years, 94% on antiretroviral treatment, 93% with HIV-RNA < 50 copies/mL, median CD4 cell count 610 cell/µL. Our analysis revealed a total of n = 8 patients who tested IgG positive during the study period. Seroprevalence was equal to 0% in the first months (March-June); this started to increase in July and reached a maximum rate of 1.59% in October 2020. The overall seroprevalence was 0.72% (8/1106, 95% CI 0.37-1.42).CONCLUSION:
our findings from this setting show a low IgG SARS-CoV-2 prevalence among PLWH as compared to data available from the general population.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Observational study
/
Randomized controlled trials
Language:
English
Year:
2021
Document Type:
Article
Affiliation country:
Diagnostics11071154
Similar
MEDLINE
...
LILACS
LIS